Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study.
O'Dwyer M, Henderson R, Naicker SD, Cahill MR, Murphy P, Mykytiv V, Quinn J, McEllistrim C, Krawczyk J, Walsh J, Lenihan E, Kenny T, Hernando A, Hirakata G, Parker I, Kinsella E, Gannon G, Natoni A, Lynch K, Ryan AE. O'Dwyer M, et al. Among authors: krawczyk j. Blood Adv. 2019 Jun 25;3(12):1815-1825. doi: 10.1182/bloodadvances.2019000010. Blood Adv. 2019. PMID: 31201169 Free PMC article. Clinical Trial.
Megakaryocyte emperipolesis in B-lymphoblastic leukaemia.
Gurney M, Krawczyk J, Paz Nuñez YE. Gurney M, et al. Among authors: krawczyk j. Br J Haematol. 2020 Feb;188(3):348. doi: 10.1111/bjh.16277. Epub 2019 Dec 17. Br J Haematol. 2020. PMID: 31845313 Free article. No abstract available.
Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.
O'Gorman P, Laubach JP, O'Dwyer ME, Krawczyk J, Yee AJ, Gilligan O, Cahill MR, Rosenblatt J, Quinn J, Murphy PT, DiPietro H, Perera MR, Crotty GM, Cummings K, Hayden PJ, Browne P, Savell A, O'Leary HM, O'Keeffe D, Masone K, Hennessy BJ, Guerrero Garcia T, Scott K, Saeed K, Bianchi G, Dowling P, Tierney C, Richardson PG. O'Gorman P, et al. Among authors: krawczyk j. Am J Hematol. 2022 May;97(5):562-573. doi: 10.1002/ajh.26491. Epub 2022 Feb 18. Am J Hematol. 2022. PMID: 35132679 Free article. Clinical Trial.
Inhibition of IRE1α RNase activity sensitizes patient-derived acute myeloid leukaemia cells to proteasome inhibitors.
Creedican S, Robinson CM, Mnich K, Islam MN, Szegezdi E, Clifford R, Krawczyk J, Patterson JB, FitzGerald SP, Summers M, Richardson C, Martin K, Gorman AM, Samali A. Creedican S, et al. Among authors: krawczyk j. J Cell Mol Med. 2022 Aug;26(16):4629-4633. doi: 10.1111/jcmm.17479. Epub 2022 Jul 13. J Cell Mol Med. 2022. PMID: 35822520 Free PMC article. No abstract available.
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment.
Swan D, Henderson R, McEllistrim C, Naicker SD, Quinn J, Cahill MR, Mykytiv V, Lenihan E, Mulvaney E, Nolan M, Parker I, Natoni A, Lynch K, Ryan AE, Szegezdi E, Krawczyk J, Murphy P, O'Dwyer M. Swan D, et al. Among authors: krawczyk j. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):847-852. doi: 10.1016/j.clml.2022.07.011. Epub 2022 Jul 21. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35985959 Clinical Trial.
Perifosine--a new option in treatment of acute myeloid leukemia?
Krawczyk J, Keane N, Swords R, O'Dwyer M, Freeman CL, Giles FJ. Krawczyk J, et al. Expert Opin Investig Drugs. 2013 Oct;22(10):1315-27. doi: 10.1517/13543784.2013.826648. Epub 2013 Aug 9. Expert Opin Investig Drugs. 2013. PMID: 23931614 Review.
235 results